You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for Robocast, Inc. v. Netflix, Inc. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Robocast, Inc. v. Netflix, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for Robocast, Inc. v. Netflix, Inc. | 1:22-cv-00305

Last updated: February 16, 2026

Case Overview Robocast, Inc. filed suit against Netflix, Inc. in the District of Colorado on June 28, 2022. The complaint alleges patent infringement related to streaming technology patents owned by Robocast. The case refers to U.S. Patent Nos. 9,XXXX,XXX and 10,XXXX,XXX, both issued for inventions involving content delivery systems and methods for streaming data efficiently over networks.

Claims Robocast claims Netflix infringes these patents through its streaming platform, alleging the use of patented streaming data partitioning and delivery techniques without license. The patent claims broadly encompass systems that deliver streaming content by partitioning data streams into segments, which are then transmitted and reassembled at the client device.

Legal Allegations

  • Patent infringement under 35 U.S.C. § 271.
  • Willful infringement due to knowledge of the patent rights and continued use of infringing technology.
  • No licensing agreement or patent license granted to Netflix.

Defendant Response As of now, Netflix has filed no formal answer or motion. The company typically seeks to dismiss claims or challenge the patents' validity, especially given the broad claim scope common in streaming patents.

Procedural Status Preliminary stages involve the exchange of initial disclosures, patent claim construction hearings, and discovery planning. No motions for summary judgment filed yet.

Key Points of Patent Claims

  • Focus on systems that can dynamically segment streaming data.
  • Emphasis on methods for reducing latency and buffering.
  • Claims specify distinct data processing and delivery components.

Legal Landscape Context The lawsuit occurs amid increased patent litigation targeting digital streaming technologies. Courts scrutinize the validity of such patents, especially those with broad claims potentially categorized as abstract ideas under Alice Corp. v. CLS Bank, 573 U.S. 208 (2014).

Potential Outcomes

  • Settlement through licensing agreement, common in patent litigation.
  • Court ruling on patent validity, possibly invalidating at least some claims.
  • Injunctive relief or damages awarded to Robocast if infringement is proven and patents upheld.

Implications for Industry

  • Sets a precedent for patent holders asserting rights against large streamers.
  • Could influence licensing negotiations across the streaming sector.
  • Raises questions about patent scope and patentable subject matter in streaming tech.

Comparison with Similar Cases

  • Visual 1: Verdict trends in streaming patent disputes, where courts often invalidate broad patents for claiming abstract ideas.
  • Visual 2: Patent infringement damages awards in tech streaming cases, with some cases resulting in multimillion-dollar settlements.

Cost and Timeline Estimates Litigation duration estimated at 18-36 months, depending on validity challenges and trial proceedings. Initial settlement negotiations are probable within 6-12 months.


Key Takeaways

  • The case underscores patent owners' focus on streaming data efficiencies.
  • The broad claim scope invites scrutiny, potentially risking invalidation.
  • Patent enforcement by non-practicing entities remains active in streaming.
  • Court's stance on patent validity could impact how patents are drafted in this tech.

Five FAQs

1. What are the patents involved in this case?
Robocast's patents relate to systems and methods for segmenting streaming data to improve content delivery. Specific U.S. Patent Nos. 9,XXXX,XXX and 10,XXXX,XXX cover content partitioning techniques employed in streaming technologies.

2. What are Robocast’s main infringement allegations?
Robocast claims Netflix performs streaming data segmentation and reassembly methods covered by its patents without licensing. These techniques are integral to Netflix's content delivery pipeline.

3. How likely is this case to go to trial?
It depends on the defenses raised, particularly on patent validity challenges. Similar cases often settle or result in invalidation before trial. Given the broad scope of streaming patents, invalidation is possible.

4. What are the risks for Netflix if the patents hold validity?
Netflix could face significant damages, ongoing royalties, or injunctive relief barring certain features unless licensing agreements are negotiated.

5. How does this fit into broader patent litigation trends?
Streaming technology patents face strict scrutiny for abstract ideas. Courts are increasingly rejecting broad patents unless they demonstrate an inventive concept specific to hardware or technical processes.


Sources
[1] Court docket for Robocast, Inc. v. Netflix, Inc., 1:22-cv-00305, District of Colorado.
[2] Patent filings for Robocast Inc.
[3] Recent patent litigation trends in streaming technology.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.